Heron Therapeutics (HRTX) Free Cash Flow (2010 - 2026)

Heron Therapeutics has reported Free Cash Flow for 17 years, with the latest figure at -$1.9 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 78.49% year-over-year to -$1.9 million; the trailing twelve-month figure through Mar 2026 stood at -$20.9 million (up 9.54% YoY), and the FY2025 full-year result was -$27.9 million, down 15.16% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$1.9 million, up from -$9.2 million in the prior quarter.
• The five-year high for Free Cash Flow was $2.9 million in Q3 2024, with the low at -$45.0 million in Q1 2022.
• Historically, Free Cash Flow has averaged -$15.4 million across 5 years, with a median of -$10.0 million in 2023.
• The largest YoY upside for Free Cash Flow was 129.48% in 2024 against a maximum downside of 663.17% in 2024.
• Heron Therapeutics' Free Cash Flow stood at -$37.9 million in 2022, then jumped by 105.81% to $2.2 million in 2023, then plunged by 663.17% to -$12.4 million in 2024, then climbed by 26.04% to -$9.2 million in 2025, then jumped by 78.97% to -$1.9 million in 2026.
• The last three Free Cash Flow figures came in at -$1.9 million (Q1 2026), -$9.2 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.